| 2015 | | Biologic response of degenerative living human nucleus pulposus cells to treatment with cytokines. | 김상현, 조기홍 |
| 2021 | | Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature | 김영배, 김지원, 김현아, 서창희, 정주양 |
| 2017 | | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab | 김현아, 서창희 |
| 2022 | | Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy | 김현아 |
| 2023 | | Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | 김현아 |
| 2017 | | Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis | 김현아, 서창희 |
| 2022 | | Curcumin inhibits the cancer-associated fibroblast-derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway | 최경숙, 함인혜, 허훈 |
| 2021 | | Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis | 김현아 |
| 2021 | | Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: Real-world data from the KOBIO registry | 김현아 |
| 2023 | | Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry | 김지원, 김현아, 서창희, 정주양 |
| 2020 | | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma | 박해심 |
| 2020 | | Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma | 박해심 |
| 2020 | | Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma | 박해심 |
| 2021 | | Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry | 김현아 |
| 2024 | | New targets for type 2-low asthma | 박해심 |
| 2016 | | Paraptosis in the anti-cancer arsenal of natural products | 김인영, 최경숙 |
| 2023 | | Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study | 김지원, 김현아, 서창희, 정주양 |
| 2017 | | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry | 김현아 |
| 2023 | | Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry | 김지원, 김현아, 서창희, 정주양 |
| 2016 | | What we know about nonsteroidal anti-inflammatory drug hypersensitivity | 박해심 |
